Details of the Drug Combination

General Information of Drug Combination (ID: DCXPVDA)

Drug Combination Name
Crizotinib Azacitidine
Indication
Disease Entry Status REF
Mixed endometrioid and clear cell carcinoma Investigative [1]
Component Drugs Crizotinib   DM4F29C Azacitidine   DMTA5OE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: IGROV1
Zero Interaction Potency (ZIP) Score: 0.03
Bliss Independence Score: 4.88
Loewe Additivity Score: 0.01
LHighest Single Agent (HSA) Score: 3.76

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Crizotinib
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Approved [2]
Crizotinib Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Proto-oncogene c-Met (MET) TTNDSF4 MET_HUMAN Modulator [8]
ALK tyrosine kinase receptor (ALK) TTPMQSO ALK_HUMAN Modulator [8]
Proto-oncogene c-Ros (ROS1) TTSZ6Y3 ROS1_HUMAN Modulator [8]
HGF/Met signaling pathway (HGF/Met pathway) TTKA5LP NOUNIPROTAC Inhibitor [9]
------------------------------------------------------------------------------------
Crizotinib Interacts with 3 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Crizotinib Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [12]
------------------------------------------------------------------------------------
Crizotinib Interacts with 45 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [13]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Decreases Activity [14]
Hepatocyte growth factor receptor (MET) OT7K55MU MET_HUMAN Increases Response To Substance [6]
ALK tyrosine kinase receptor (ALK) OTV3P4V8 ALK_HUMAN Decreases Response To Substance [15]
Prominin-1 (PROM1) OTBHV8NX PROM1_HUMAN Decreases Expression [5]
CD44 antigen (CD44) OT9TTJ41 CD44_HUMAN Decreases Expression [5]
Epithelial cell adhesion molecule (EPCAM) OTHBZK5X EPCAM_HUMAN Decreases Expression [5]
Cytidine deaminase (CDA) OT3HXP6N CDD_HUMAN Decreases Expression [5]
Insulin-induced gene 1 protein (INSIG1) OTZF5X1D INSI1_HUMAN Increases Expression [16]
Acyl-CoA 6-desaturase (FADS2) OTUX531P FADS2_HUMAN Increases Expression [16]
3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) OTRT3F3U HMDH_HUMAN Increases Expression [16]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [16]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Increases Expression [16]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [16]
Hydroxymethylglutaryl-CoA synthase, cytoplasmic (HMGCS1) OTCO26FV HMCS1_HUMAN Increases Expression [16]
Sterol regulatory element-binding protein 2 (SREBF2) OTBXUNPL SRBP2_HUMAN Increases Expression [16]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [16]
Acetyl-CoA carboxylase 1 (ACACA) OT5CQPZY ACACA_HUMAN Increases Phosphorylation [16]
Voltage-dependent L-type calcium channel subunit alpha-1C (CACNA1C) OT6KFNMS CAC1C_HUMAN Decreases Activity [16]
Sodium channel protein type 5 subunit alpha (SCN5A) OTGYZWR6 SCN5A_HUMAN Decreases Activity [16]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [6]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Increases Expression [6]
Follitropin subunit beta (FSHB) OTGLS283 FSHB_HUMAN Decreases Secretion [17]
Lutropin subunit beta (LHB) OT5GBOVJ LSHB_HUMAN Decreases Secretion [17]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Activity [18]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [19]
Tissue factor (F3) OT3MSU3B TF_HUMAN Increases Expression [20]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Phosphorylation [19]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [21]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [22]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [22]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Phosphorylation [23]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [24]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1) OTZRWTGA IQGA1_HUMAN Decreases Phosphorylation [25]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [24]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [6]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [26]
Echinoderm microtubule-associated protein-like 4 (EML4) OTJC45TA EMAL4_HUMAN Increases Mutagenesis [22]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Decreases Activity [14]
GTPase KRas (KRAS) OT78QCN8 RASK_HUMAN Decreases Response To Substance [27]
Pro-epidermal growth factor (EGF) OTANRJ0L EGF_HUMAN Decreases Response To Substance [23]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Response To Substance [27]
Mast/stem cell growth factor receptor Kit (KIT) OTHUY3VZ KIT_HUMAN Decreases Response To Substance [15]
Proheparin-binding EGF-like growth factor (HBEGF) OTLU00JS HBEGF_HUMAN Decreases Response To Substance [23]
Protransforming growth factor alpha (TGFA) OTPD1LL9 TGFA_HUMAN Decreases Response To Substance [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 45 DOT(s)
Indication(s) of Azacitidine
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [3]
Chronic myelomonocytic leukemia N.A. Approved [3]
Leukemia N.A. Approved [3]
Myelodysplastic syndrome 2A37 Approved [4]
Myeloproliferative neoplasm 2A20 Approved [3]
Plasma cell myeloma 2A83.1 Approved [3]
Azacitidine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA [cytosine-5]-methyltransferase (DNMT) TTHVCUP NOUNIPROTAC Inhibitor [32]
------------------------------------------------------------------------------------
Azacitidine Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytidine aminohydrolase (CDA) DEKEDRC CDD_HUMAN Metabolism [33]
Cytidine deaminase (cdd) DEYILK4 E0TLJ6_MYCHH Metabolism [34]
------------------------------------------------------------------------------------
Azacitidine Interacts with 275 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Affects Expression [35]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Increases Expression [36]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Increases Expression [36]
Aryl hydrocarbon receptor (AHR) OTFE4EYE AHR_HUMAN Increases Expression [36]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Increases Expression [36]
Sulfotransferase 1C2 (SULT1C2) OT07MMZS ST1C2_HUMAN Increases Expression [28]
Phospholipid phosphatase 1 (PLPP1) OT0IIMI5 PLPP1_HUMAN Increases Expression [28]
Tectonin beta-propeller repeat-containing protein 2 (TECPR2) OT1UFECZ TCPR2_HUMAN Increases Expression [28]
TBC1 domain family member 4 (TBC1D4) OTK66C40 TBCD4_HUMAN Decreases Expression [28]
Multiple epidermal growth factor-like domains protein 6 (MEGF6) OTEUYTP1 MEGF6_HUMAN Decreases Expression [28]
Stanniocalcin-2 (STC2) OT86YP8G STC2_HUMAN Decreases Expression [28]
Integrin beta-2 (ITGB2) OTEKPEPR ITB2_HUMAN Decreases Expression [28]
Protein S100-A9 (S100A9) OTOARHCS S10A9_HUMAN Increases Expression [28]
Receptor-type tyrosine-protein phosphatase C (PTPRC) OT6KOR77 PTPRC_HUMAN Increases Expression [28]
Delta-aminolevulinic acid dehydratase (ALAD) OTHM9GSH HEM2_HUMAN Decreases Expression [28]
Hepatocyte growth factor (HGF) OTGHUA23 HGF_HUMAN Increases Expression [28]
Heat shock 70 kDa protein 6 (HSPA6) OTH4S7WB HSP76_HUMAN Increases Expression [28]
Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) OT4L2SSB GBRB1_HUMAN Increases Expression [28]
Transcription factor E3 (TFE3) OTM99ZWH TFE3_HUMAN Increases Expression [28]
Pro-thyrotropin-releasing hormone (TRH) OT02UY2V TRH_HUMAN Decreases Expression [28]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Increases Expression [28]
Protein PML (PML) OT6SM2GD PML_HUMAN Increases Expression [28]
DNA-binding protein inhibitor ID-1 (ID1) OTKGNZN5 ID1_HUMAN Increases Expression [28]
Cyclin-dependent kinase 4 inhibitor B (CDKN2B) OTAG24N1 CDN2B_HUMAN Decreases Methylation [28]
LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1) OT729S0T LIMS1_HUMAN Increases Expression [28]
E3 SUMO-protein ligase RanBP2 (RANBP2) OTFG5CVF RBP2_HUMAN Increases Expression [28]
Cyclin-dependent kinase inhibitor 1C (CDKN1C) OTASTJ3Q CDN1C_HUMAN Increases Expression [28]
Ras-related protein Rab-13 (RAB13) OTIQ484I RAB13_HUMAN Decreases Methylation [28]
Lysozyme C (LYZ) OTD7H0G6 LYSC_HUMAN Increases Expression [28]
Claudin-10 (CLDN10) OT2CVAKY CLD10_HUMAN Decreases Expression [28]
Sushi repeat-containing protein SRPX (SRPX) OT5B9LXS SRPX_HUMAN Decreases Expression [28]
Protein delta homolog 1 (DLK1) OTE1VLNB DLK1_HUMAN Decreases Methylation [28]
DNA-binding protein inhibitor ID-3 (ID3) OTUULW5Z ID3_HUMAN Increases Expression [28]
Collagen alpha-1(XIV) chain (COL14A1) OTLNJ13O COEA1_HUMAN Increases Expression [28]
Equilibrative nucleoside transporter 2 (SLC29A2) OTUAOB8T S29A2_HUMAN Decreases Expression [28]
Cytohesin-1 (CYTH1) OTYH9NRJ CYH1_HUMAN Increases Expression [28]
C3a anaphylatoxin chemotactic receptor (C3AR1) OT8J0TF8 C3AR_HUMAN Increases Expression [28]
DNA dC->dU-editing enzyme APOBEC-3F (APOBEC3F) OT750IJM ABC3F_HUMAN Increases Expression [28]
Angiogenic factor with G patch and FHA domains 1 (AGGF1) OTA7U2T8 AGGF1_HUMAN Increases Expression [28]
E3 ubiquitin-protein ligase Praja-1 (PJA1) OTFKTMEI PJA1_HUMAN Increases Expression [28]
Caspase-10 (CASP10) OTE6J88E CASPA_HUMAN Increases Expression [28]
Tetraspanin-32 (TSPAN32) OTSXW7EW TSN32_HUMAN Decreases Expression [28]
Tribbles homolog 1 (TRIB1) OTPEO17G TRIB1_HUMAN Decreases Expression [28]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) OTT5JX1F LITAF_HUMAN Decreases Expression [28]
Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha (PIP5K1A) OTVTB5R5 PI51A_HUMAN Decreases Expression [28]
Centromere protein O (CENPO) OTXAH83Y CENPO_HUMAN Increases Expression [28]
Iron-sulfur cluster assembly 1 homolog, mitochondrial (ISCA1) OTU230MC ISCA1_HUMAN Increases Expression [28]
E3 ubiquitin-protein ligase TRIM8 (TRIM8) OTS6JFR0 TRIM8_HUMAN Increases Expression [28]
Uncharacterized protein C6orf62 (C6ORF62) OTGK4G35 CF062_HUMAN Increases Expression [28]
Metal transporter CNNM2 (CNNM2) OTZHO8WU CNNM2_HUMAN Decreases Expression [28]
Pantothenate kinase 3 (PANK3) OT77CFJ6 PANK3_HUMAN Decreases Expression [28]
DNA dC->dU-editing enzyme APOBEC-3G (APOBEC3G) OT410VP5 ABC3G_HUMAN Increases Expression [28]
Neuritin (NRN1) OTWJG0SO NRN1_HUMAN Decreases Expression [28]
NTF2-related export protein 2 (NXT2) OTK82YVT NXT2_HUMAN Increases Expression [28]
THUMP domain-containing protein 1 (THUMPD1) OTKU8KWH THUM1_HUMAN Increases Expression [28]
Protein FAM8A1 (FAM8A1) OT1QVTGS FA8A1_HUMAN Increases Expression [28]
Type 2 lactosamine alpha-2,3-sialyltransferase (ST3GAL6) OTB17Q43 SIA10_HUMAN Increases Expression [28]
Methionine-R-sulfoxide reductase B2, mitochondrial (MSRB2) OTURGRA8 MSRB2_HUMAN Increases Expression [28]
Mitotic spindle assembly checkpoint protein MAD1 (MAD1L1) OTJCX8K9 MD1L1_HUMAN Decreases Expression [28]
Signal-regulatory protein beta-1 (SIRPB1) OTGHALWJ SIRB1_HUMAN Decreases Expression [29]
Syntenin-1 (SDCBP) OTS3NCC5 SDCB1_HUMAN Decreases Expression [29]
Complexin-1 (CPLX1) OT7UIGTP CPLX1_HUMAN Increases Expression [29]
Nephrocystin-1 (NPHP1) OTZHCFFQ NPHP1_HUMAN Increases Expression [29]
Phosphatase and actin regulator 2 (PHACTR2) OTWMX2A8 PHAR2_HUMAN Increases Expression [29]
Nuclear factor of activated T-cells, cytoplasmic 1 (NFATC1) OT4TMERS NFAC1_HUMAN Increases Expression [29]
Acyl-CoA 6-desaturase (FADS2) OTUX531P FADS2_HUMAN Decreases Expression [29]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Increases Expression [29]
Cystatin-C (CST3) OTNZ6AO4 CYTC_HUMAN Increases Expression [29]
Cystatin-S (CST4) OTXXM8EH CYTS_HUMAN Increases Expression [29]
Interstitial collagenase (MMP1) OTI4I2V1 MMP1_HUMAN Increases Expression [29]
Integrin beta-1 (ITGB1) OT6G1IAR ITB1_HUMAN Decreases Expression [29]
Keratin, type II cytoskeletal 8 (KRT8) OTTM4X11 K2C8_HUMAN Increases Expression [29]
Neurofilament light polypeptide (NEFL) OTQESJV4 NFL_HUMAN Increases Expression [29]
Protein disulfide-isomerase (P4HB) OTTYNYPF PDIA1_HUMAN Increases Expression [29]
Decorin (DCN) OTWLJL7K PGS2_HUMAN Decreases Expression [29]
Profilin-1 (PFN1) OTHTGA1H PROF1_HUMAN Increases Expression [29]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Decreases Expression [29]
Tropomyosin beta chain (TPM2) OTA1L0P8 TPM2_HUMAN Increases Expression [29]
Transcription factor Sp1 (SP1) OTISPT4X SP1_HUMAN Decreases Expression [29]
Keratin, type I cytoskeletal 19 (KRT19) OTDGDQ75 K1C19_HUMAN Increases Expression [29]
Insulin-like growth factor-binding protein 1 (IGFBP1) OT6UQV2K IBP1_HUMAN Increases Expression [29]
Small ribosomal subunit protein uS2 (RPSA) OTJZHEGT RSSA_HUMAN Decreases Expression [29]
Glycodelin (PAEP) OTQA0NV4 PAEP_HUMAN Decreases Expression [29]
E3 SUMO-protein ligase EGR2 (EGR2) OTAVQ78J EGR2_HUMAN Increases Expression [29]
Pregnancy-specific beta-1-glycoprotein 1 (PSG1) OT1U4ZZW PSG1_HUMAN Increases Expression [29]
Collagen alpha-3(VI) chain (COL6A3) OTAS6R6I CO6A3_HUMAN Decreases Expression [29]
Parathyroid hormone-related protein (PTHLH) OTI1JF13 PTHR_HUMAN Decreases Expression [29]
Plastin-3 (PLS3) OTYBM4PK PLST_HUMAN Decreases Expression [29]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Decreases Expression [29]
Pyruvate kinase PKM (PKM) OTLHHMC2 KPYM_HUMAN Increases Expression [29]
Carboxypeptidase E (CPE) OTXNTV79 CBPE_HUMAN Increases Expression [29]
High mobility group protein HMG-I/HMG-Y (HMGA1) OTQUSHPX HMGA1_HUMAN Increases Expression [29]
Gap junction alpha-1 protein (GJA1) OTT94MKL CXA1_HUMAN Decreases Expression [29]
Desmin (DES) OTI09KBW DESM_HUMAN Increases Expression [29]
Plasma membrane calcium-transporting ATPase 1 (ATP2B1) OT5MXG9W AT2B1_HUMAN Decreases Expression [29]
Cyclin-A2 (CCNA2) OTPHHYZJ CCNA2_HUMAN Decreases Expression [29]
5'-nucleotidase (NT5E) OT7J5LT6 5NTD_HUMAN Increases Expression [29]
Fibroblast growth factor 7 (FGF7) OTGK6ANL FGF7_HUMAN Decreases Expression [29]
Insulin-like growth factor-binding protein 4 (IGFBP4) OT2HZRBD IBP4_HUMAN Increases Expression [29]
Transcription elongation factor A protein 1 (TCEA1) OTBFO594 TCEA1_HUMAN Decreases Expression [29]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Increases Expression [29]
Tenascin (TNC) OTK4FSHR TENA_HUMAN Decreases Expression [29]
V-type proton ATPase 16 kDa proteolipid subunit c (ATP6V0C) OTKPL09B VATL_HUMAN Increases Expression [29]
Protein ITPRID2 (ITPRID2) OTO3JDX5 ITPI2_HUMAN Increases Expression [29]
Dual specificity protein phosphatase 1 (DUSP1) OTN6BR75 DUS1_HUMAN Increases Expression [29]
Interleukin-12 subunit beta (IL12B) OT0JF8A3 IL12B_HUMAN Increases Expression [29]
Neurotensin/neuromedin N (NTS) OTPGDNQS NEUT_HUMAN Decreases Expression [29]
Guanylate-binding protein 2 (GBP2) OTVU4G07 GBP2_HUMAN Decreases Expression [29]
MHC class II transactivator (CIITA) OTRJNZFO C2TA_HUMAN Increases Expression [29]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [29]
Exosome RNA helicase MTR4 (MTREX) OTSQY30V MTREX_HUMAN Increases Expression [29]
Alpha-S1-casein (CSN1S1) OTXOW6XJ CASA1_HUMAN Increases Expression [29]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Decreases Expression [29]
Homeobox protein Hox-A1 (HOXA1) OTMSOJ7D HXA1_HUMAN Increases Expression [29]
Ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1) OT6E2OW6 ENTP1_HUMAN Increases Expression [29]
Ephrin-A3 (EFNA3) OTJGOUMZ EFNA3_HUMAN Increases Expression [29]
GPI-linked NAD(P)(+)--arginine ADP-ribosyltransferase 1 (ART1) OT7FBG5W NAR1_HUMAN Increases Expression [29]
Branched-chain-amino-acid aminotransferase, cytosolic (BCAT1) OTYHXLWZ BCAT1_HUMAN Decreases Expression [29]
Microfibrillar-associated protein 2 (MFAP2) OTMHVBTV MFAP2_HUMAN Decreases Expression [29]
Laminin subunit beta-2 (LAMB2) OT71OI2Y LAMB2_HUMAN Increases Expression [29]
NHP2-like protein 1 (SNU13) OTH56TIH NH2L1_HUMAN Increases Expression [29]
Homeobox protein DLX-6 (DLX6) OT0FIJHY DLX6_HUMAN Increases Expression [29]
Neurotrypsin (PRSS12) OT1MYL3L NETR_HUMAN Decreases Expression [29]
Elongation factor 1-alpha 1 (EEF1A1) OT00THXS EF1A1_HUMAN Decreases Expression [29]
Microtubule-associated protein 1A (MAP1A) OTHO8K43 MAP1A_HUMAN Decreases Expression [29]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [29]
Cytochrome c oxidase subunit 6A2, mitochondrial (COX6A2) OTQR5SXD CX6A2_HUMAN Increases Expression [29]
cAMP-responsive element modulator (CREM) OTJIJ5AL CREM_HUMAN Decreases Expression [29]
Caldesmon (CALD1) OTNJKJ6Q CALD1_HUMAN Increases Expression [29]
ATP-dependent RNA helicase A (DHX9) OT5AAOQI DHX9_HUMAN Decreases Expression [29]
Serine/threonine-protein kinase PAK 1 (PAK1) OT17LZNZ PAK1_HUMAN Increases Expression [29]
Dual specificity mitogen-activated protein kinase kinase 5 (MAP2K5) OT6T408U MP2K5_HUMAN Decreases Expression [29]
Chitotriosidase-1 (CHIT1) OTPQR0A6 CHIT1_HUMAN Increases Expression [29]
Ras and Rab interactor 1 (RIN1) OTPBROUD RIN1_HUMAN Increases Expression [29]
Keratin, type I cuticular Ha2 (KRT32) OTZCGZYT K1H2_HUMAN Increases Expression [29]
Semaphorin-3A (SEMA3A) OTQJSV7W SEM3A_HUMAN Increases Expression [29]
Ras GTPase-activating protein 3 (RASA3) OT9C54MN RASA3_HUMAN Increases Expression [29]
Mediator of DNA damage checkpoint protein 1 (MDC1) OTEUQH4J MDC1_HUMAN Increases Expression [29]
Transmembrane glycoprotein NMB (GPNMB) OTB7KQKV GPNMB_HUMAN Decreases Expression [29]
Mortality factor 4-like protein 2 (MORF4L2) OT8OI3EC MO4L2_HUMAN Decreases Expression [29]
kinase isozyme 1, mitochondrial (PDK1) OTMABK9Z PDK1_HUMAN Increases Expression [29]
Serine/threonine-protein kinase 38 (STK38) OTKMYCYR STK38_HUMAN Decreases Expression [29]
Serine/threonine-protein phosphatase 2A activator (PTPA) OTRGFOI7 PTPA_HUMAN Increases Expression [29]
Reticulocalbin-1 (RCN1) OT3JBGAG RCN1_HUMAN Decreases Expression [29]
Olfactory receptor 8B8 (OR8B8) OTCISNYV OR8B8_HUMAN Increases Expression [29]
Leukotriene B4 receptor 1 (LTB4R) OT3SRH4H LT4R1_HUMAN Decreases Expression [29]
Serine/arginine-rich splicing factor 7 (SRSF7) OTRS4W4S SRSF7_HUMAN Decreases Expression [29]
Guanylate kinase (GUK1) OTLI0HRU KGUA_HUMAN Increases Expression [29]
Filamin A-interacting protein 1-like (FILIP1L) OTPY8IMS FIL1L_HUMAN Decreases Expression [29]
Nucleolar MIF4G domain-containing protein 1 (NOM1) OTWZSJJC NOM1_HUMAN Decreases Expression [29]
Opioid growth factor receptor-like protein 1 (OGFRL1) OT6QGBYE OGRL1_HUMAN Increases Expression [29]
Serine/threonine-protein kinase MRCK alpha (CDC42BPA) OTCPFOSA MRCKA_HUMAN Decreases Expression [29]
Extracellular sulfatase Sulf-1 (SULF1) OTJCNCO0 SULF1_HUMAN Decreases Expression [29]
N-acetyllactosaminide beta-1,6-N-acetylglucosaminyl-transferase (GCNT2) OTRUIMC4 GNT2A_HUMAN Decreases Expression [29]
Oxidation resistance protein 1 (OXR1) OTPIDMT3 OXR1_HUMAN Increases Expression [29]
Alpha-2,8-sialyltransferase 8B (ST8SIA2) OTRBBBD8 SIA8B_HUMAN Decreases Expression [29]
Type II iodothyronine deiodinase (DIO2) OTGPNSLH IOD2_HUMAN Decreases Expression [29]
G-patch domain and KOW motifs-containing protein (GPKOW) OTGS3H0M GPKOW_HUMAN Increases Expression [29]
Rho guanine nucleotide exchange factor 2 (ARHGEF2) OTBQTFRT ARHG2_HUMAN Decreases Expression [29]
Homogentisate 1,2-dioxygenase (HGD) OTTKLQOO HGD_HUMAN Increases Expression [29]
Secretory carrier-associated membrane protein 4 (SCAMP4) OTSCZTJ5 SCAM4_HUMAN Increases Expression [29]
Protein bicaudal D homolog 1 (BICD1) OT78IYPF BICD1_HUMAN Decreases Expression [29]
Ankyrin repeat and SOCS box protein 2 (ASB2) OTF9LV7L ASB2_HUMAN Increases Expression [29]
Eyes absent homolog 1 (EYA1) OTHU807A EYA1_HUMAN Decreases Expression [29]
Bcl-2-like protein 13 (BCL2L13) OT2VRFTM B2L13_HUMAN Increases Expression [29]
RNA helicase Mov10l1 (MOV10L1) OTP978LK M10L1_HUMAN Increases Expression [29]
Rac GTPase-activating protein 1 (RACGAP1) OTQE8IEH RGAP1_HUMAN Increases Expression [29]
Ras-related protein Rab-1B (RAB1B) OTAFCUAS RAB1B_HUMAN Increases Expression [29]
Semaphorin-6C (SEMA6C) OT1N59T5 SEM6C_HUMAN Increases Expression [29]
Sentrin-specific protease 3 (SENP3) OTFQDOMC SENP3_HUMAN Increases Expression [29]
Ribonuclease P protein subunit p21 (RPP21) OT53MDNE RPP21_HUMAN Increases Expression [29]
Protocadherin-18 (PCDH18) OTTLQWRN PCD18_HUMAN Decreases Expression [29]
Protein S100-A14 (S100A14) OTVFJJ91 S10AE_HUMAN Decreases Expression [29]
Tryptase gamma (TPSG1) OTDESHKT TRYG1_HUMAN Decreases Expression [29]
Rho GTPase-activating protein 35 (ARHGAP35) OTJ8POG0 RHG35_HUMAN Increases Expression [29]
Neuroligin-3 (NLGN3) OTKDEC1Q NLGN3_HUMAN Increases Expression [29]
Polycystin-2-like protein 1 (PKD2L1) OT1KJDAT PK2L1_HUMAN Increases Expression [29]
A disintegrin and metalloproteinase with thrombospondin motifs 1 (ADAMTS1) OTTLJH8W ATS1_HUMAN Decreases Expression [29]
Cytoplasmic phosphatidylinositol transfer protein 1 (PITPNC1) OT64TTGC PITC1_HUMAN Decreases Expression [29]
Transcription factor SOX-13 (SOX13) OTCIF6KC SOX13_HUMAN Decreases Expression [29]
Afadin- and alpha-actinin-binding protein (SSX2IP) OTEIZ7N1 ADIP_HUMAN Increases Expression [29]
Transmembrane emp24 domain-containing protein 3 (TMED3) OTNOPHHC TMED3_HUMAN Increases Expression [29]
Protocadherin beta-4 (PCDHB4) OTF665E0 PCDB4_HUMAN Decreases Expression [29]
Protocadherin beta-14 (PCDHB14) OTFZF1ST PCDBE_HUMAN Decreases Expression [29]
Adenylate kinase isoenzyme 5 (AK5) OTTGXLOT KAD5_HUMAN Increases Expression [29]
Albumin (ALB) OTVMM513 ALBU_HUMAN Increases Expression [37]
Alpha-fetoprotein (AFP) OT9GG3ZI FETA_HUMAN Increases Expression [37]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [37]
Tyrosine aminotransferase (TAT) OT2CJ91O ATTY_HUMAN Increases Expression [37]
Hepatocyte nuclear factor 4-alpha (HNF4A) OTY1TOAB HNF4A_HUMAN Increases Expression [37]
CCAAT/enhancer-binding protein alpha (CEBPA) OTOM9OE4 CEBPA_HUMAN Increases Expression [37]
Hematopoietically-expressed homeobox protein HHEX (HHEX) OTLIUVYX HHEX_HUMAN Increases Expression [37]
Suppressor of cytokine signaling 3 (SOCS3) OTY183WJ SOCS3_HUMAN Affects Expression [35]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Expression [38]
Aquaporin-9 (AQP9) OTLGH5ZY AQP9_HUMAN Increases Expression [39]
Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-7 (GNG7) OTHS1L0E GBG7_HUMAN Affects Methylation [40]
Claudin-7 (CLDN7) OTNE0XHQ CLD7_HUMAN Decreases Expression [41]
Claudin-9 (CLDN9) OTCKI2IZ CLD9_HUMAN Increases Expression [42]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [38]
Calcitonin (CALCA) OTZ11LHB CALC_HUMAN Decreases Methylation [43]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Increases Response To Substance [44]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Expression [45]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [46]
Interleukin-4 (IL4) OTOXBWAU IL4_HUMAN Affects Methylation [47]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Affects Methylation [47]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Increases Expression [48]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Increases Expression [49]
L-lactate dehydrogenase B chain (LDHB) OT9B1CT3 LDHB_HUMAN Increases Expression [50]
Thyroid peroxidase (TPO) OTJJLL20 PERT_HUMAN Increases Expression [51]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Increases Expression [49]
Histone H1.0 (H1-0) OTRLJK4Z H10_HUMAN Increases Expression [52]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Affects Expression [35]
Gamma-enolase (ENO2) OTRODL0T ENOG_HUMAN Decreases Expression [53]
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Increases Expression [49]
Microtubule-associated protein tau (MAPT) OTMTP2Z7 TAU_HUMAN Decreases Expression [54]
Chromogranin-A (CHGA) OTXYX5JH CMGA_HUMAN Decreases Expression [53]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [49]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [55]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Expression [53]
15-hydroxyprostaglandin dehydrogenase (HPGD) OTYZI6JB PGDH_HUMAN Decreases Methylation [56]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [57]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Increases Expression [58]
Thyrotropin receptor (TSHR) OT0BC8LB TSHR_HUMAN Increases Expression [51]
Hepatocyte nuclear factor 1-alpha (HNF1A) OT9DOUKL HNF1A_HUMAN Increases Expression [39]
Fibulin-1 (FBLN1) OT5MHHOP FBLN1_HUMAN Increases Expression [48]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [59]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [49]
DNA cytosine-5)-methyltransferase 1 (DNMT1) OTM2DGTK DNMT1_HUMAN Decreases Expression [60]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Affects Methylation [61]
Oxytocin receptor (OXTR) OT7WFW4U OXYR_HUMAN Decreases Expression [48]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Affects Expression [35]
Cyclin-dependent kinase inhibitor 2A (CDKN2A) OTN0ZWAE CDN2A_HUMAN Decreases Methylation [62]
Melanoma-associated antigen 1 (MAGEA1) OTXAO193 MAGA1_HUMAN Decreases Methylation [62]
Melanoma-associated antigen 3 (MAGEA3) OTW3Y5M4 MAGA3_HUMAN Increases Expression [63]
Killer cell immunoglobulin-like receptor 2DL1 (KIR2DL1) OTL1LBQJ KI2L1_HUMAN Increases Expression [64]
Killer cell immunoglobulin-like receptor 2DL2 (KIR2DL2) OTOVUTJD KI2L2_HUMAN Increases Expression [64]
Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) OTFCN53B KI2L3_HUMAN Increases Expression [64]
Killer cell immunoglobulin-like receptor 3DL1 (KIR3DL1) OTPOSXFX KI3L1_HUMAN Increases Expression [64]
Killer cell immunoglobulin-like receptor 2DS4 (KIR2DS4) OT00N6UJ KI2S4_HUMAN Increases Expression [64]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Response To Substance [44]
Stromal cell-derived factor 1 (CXCL12) OT2QX5LL SDF1_HUMAN Increases Expression [65]
Tuberin (TSC2) OT47LWI9 TSC2_HUMAN Increases Expression [66]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [44]
High mobility group protein HMGI-C (HMGA2) OTBMBHHL HMGA2_HUMAN Increases Expression [48]
Homeobox protein Nkx-2.5 (NKX2-5) OTS1SAWM NKX25_HUMAN Increases Expression [67]
Death-associated protein kinase 1 (DAPK1) OTNCNUCO DAPK1_HUMAN Affects Methylation [68]
Claudin-6 (CLDN6) OTEN8ID2 CLD6_HUMAN Increases Expression [42]
Claudin-8 (CLDN8) OT7IIWXG CLD8_HUMAN Increases Expression [42]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [48]
Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform (PPP2CA) OT83PT85 PP2AA_HUMAN Increases Expression [69]
Cyclin-A1 (CCNA1) OTX4HD45 CCNA1_HUMAN Decreases Expression [70]
Heat shock factor protein 1 (HSF1) OTYNJ4KP HSF1_HUMAN Decreases Activity [71]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Affects Localization [35]
Tight junction protein ZO-1 (TJP1) OTBDCUPK ZO1_HUMAN Increases Expression [42]
Dihydropyrimidine dehydrogenase (DPYD) OTWRF2NR DPYD_HUMAN Decreases Methylation [72]
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) OT4SO7J4 BNIP3_HUMAN Increases Expression [73]
N-myc-interactor (NMI) OTYVG3NM NMI_HUMAN Increases Expression [48]
NAD(P) transhydrogenase, mitochondrial (NNT) OTAIOGZK NNTM_HUMAN Increases Expression [41]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Affects Methylation [74]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Expression [75]
Cyclin-G2 (CCNG2) OTII38K2 CCNG2_HUMAN Decreases Expression [48]
Occludin (OCLN) OTSUTVWL OCLN_HUMAN Increases Expression [42]
kinase isozyme 4, mitochondrial (PDK4) OTCMHMBZ PDK4_HUMAN Decreases Methylation [76]
Dual specificity protein phosphatase 6 (DUSP6) OT4H6RKW DUS6_HUMAN Increases Expression [48]
Ribonucleoside-diphosphate reductase subunit M2 B (RRM2B) OTE8GBUR RIR2B_HUMAN Increases Expression [77]
Sodium/iodide cotransporter (SLC5A5) OTU7E9G7 SC5A5_HUMAN Increases Expression [78]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Increases Expression [48]
Killer cell immunoglobulin-like receptor 2DL4 (KIR2DL4) OTXN18OA KI2L4_HUMAN Increases Expression [64]
Protein Niban 1 (NIBAN1) OTYOLI12 NIBA1_HUMAN Increases Expression [48]
Calcium homeostasis modulator protein 2 (CALHM2) OTWWM6HI CAHM2_HUMAN Increases Expression [41]
Homeobox protein SIX2 (SIX2) OTYOVGSC SIX2_HUMAN Decreases Expression [41]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 (PLCB1) OT9HYT7A PLCB1_HUMAN Increases Expression [79]
Sal-like protein 4 (SALL4) OTC08PR5 SALL4_HUMAN Affects Methylation [31]
Transcription factor MafB (MAFB) OTH2N3T8 MAFB_HUMAN Increases Expression [41]
Sodium/nucleoside cotransporter 1 (SLC28A1) OTXWVV9O S28A1_HUMAN Increases Response To Substance [80]
------------------------------------------------------------------------------------
⏷ Show the Full List of 275 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Anaplastic large cell lymphoma DCUMX1B SR Investigative [1]
Cutaneous melanoma DCXUT6W SK-MEL-5 Investigative [1]
Invasive ductal carcinoma DCK2DQD T-47D Investigative [81]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4903).
3 Azacitidine FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6796).
5 Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. Curr Pharm Des. 2013;19(5):940-50.
6 Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012 Jul;11(7):1557-64. doi: 10.1158/1535-7163.MCT-11-0934. Epub 2012 Jun 22.
7 Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALK-positive anaplastic large cell lymphoma. Cell Signal. 2012 Apr;24(4):852-8. doi: 10.1016/j.cellsig.2011.11.020. Epub 2011 Dec 8.
8 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
9 Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.Drug Des Devel Ther. 2015 Aug 26;9:4897-907.
10 Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer. 2014 Mar 15;134(6):1484-94.
11 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
12 Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 2013 Jun 1;70(11):943-7.
13 Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos. 2013 Feb;41(2):343-52.
14 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
15 Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med. 2012 Feb 8;4(120):120ra17. doi: 10.1126/scitranslmed.3003316. Epub 2012 Jan 25.
16 Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicol Appl Pharmacol. 2013 Oct 1;272(1):245-55.
17 Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer. 2012 Nov 1;118(21):5302-9. doi: 10.1002/cncr.27450. Epub 2012 Apr 4.
18 Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011 Sep 22;54(18):6342-63. doi: 10.1021/jm2007613. Epub 2011 Aug 18.
19 ROS-dependent DNA damage contributes to crizotinib-induced hepatotoxicity via the apoptotic pathway. Toxicol Appl Pharmacol. 2019 Nov 15;383:114768. doi: 10.1016/j.taap.2019.114768. Epub 2019 Oct 19.
20 Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects. Int J Mol Sci. 2015 Jan 5;16(1):1008-29. doi: 10.3390/ijms16011008.
21 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
22 Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18.
23 Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 2012 Jul 1;18(13):3592-602. doi: 10.1158/1078-0432.CCR-11-2972. Epub 2012 May 2.
24 Crizotinib-resistant mutants of EML4-ALK identified through an accelerated mutagenesis screen. Chem Biol Drug Des. 2011 Dec;78(6):999-1005. doi: 10.1111/j.1747-0285.2011.01239.x. Epub 2011 Oct 31.
25 Tyrosine phosphorylation of the scaffold protein IQGAP1 in the MET pathway alters function. J Biol Chem. 2020 Dec 25;295(52):18105-18121. doi: 10.1074/jbc.RA120.015891. Epub 2020 Oct 21.
26 Keratinocytes apoptosis contributes to crizotinib induced-erythroderma. Toxicol Lett. 2020 Feb 1;319:102-110. doi: 10.1016/j.toxlet.2019.11.007. Epub 2019 Nov 7.
27 Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012 Mar 1;18(5):1472-82. doi: 10.1158/1078-0432.CCR-11-2906. Epub 2012 Jan 10.
28 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 2009 Jun;23(6):1019-28.
29 The effect of DNA methylation inhibitor 5-Aza-2'-deoxycytidine on human endometrial stromal cells. Hum Reprod. 2010 Nov;25(11):2859-69.
30 Combination of DNA methylation inhibitor 5-azacytidine and arsenic trioxide has synergistic activity in myeloma. Eur J Haematol. 2009 Mar;82(3):176-83. doi: 10.1111/j.1600-0609.2008.01189.x. Epub 2008 Dec 5.
31 Novel approach for detecting global epigenetic alterations associated with tumor cell aneuploidy. Int J Cancer. 2007 Oct 1;121(7):1487-93. doi: 10.1002/ijc.22847.
32 The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid l... Leukemia. 2009 Jun;23(6):1019-28.
33 A pilot pharmacokinetic study of oral azacitidine. Leukemia. 2008 Sep;22(9):1680-4.
34 Mycoplasma hyorhinis-encoded cytidine deaminase efficiently inactivates cytosine-based anticancer drugs. FEBS Open Bio. 2015 Aug 3;5:634-9.
35 The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma. Haematologica. 2008 Jun;93(6):860-9. doi: 10.3324/haematol.12261. Epub 2008 Apr 28.
36 Effects of histone deacetylation and DNA methylation on the constitutive and TCDD-inducible expressions of the human CYP1 family in MCF-7 and HeLa cells. Toxicol Lett. 2003 Sep 30;144(2):247-56.
37 Self-assembled 3D spheroids and hollow-fibre bioreactors improve MSC-derived hepatocyte-like cell maturation in vitro. Arch Toxicol. 2017 Apr;91(4):1815-1832.
38 Alpha anomer of 5-aza-2'-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells. Biochem Pharmacol. 2008 Feb 15;75(4):965-72. doi: 10.1016/j.bcp.2007.10.018. Epub 2007 Oct 22.
39 Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9. J Hematol Oncol. 2015 May 8;8:46. doi: 10.1186/s13045-015-0143-3.
40 Clinical significance of the reduced expression of G protein gamma 7 (GNG7) in oesophageal cancer. Br J Cancer. 2008 Jan 29;98(2):410-7. doi: 10.1038/sj.bjc.6604124. Epub 2008 Jan 22.
41 CRISPR-based DNA methylation editing of NNT rescues the cisplatin resistance of lung cancer cells by reducing autophagy. Arch Toxicol. 2023 Feb;97(2):441-456. doi: 10.1007/s00204-022-03404-0. Epub 2022 Nov 6.
42 Prevention of murine experimental corneal trauma by epigenetic events regulating claudin 6 and claudin 9. Jpn J Ophthalmol. 2008 May-Jun;52(3):195-203. doi: 10.1007/s10384-008-0524-z. Epub 2008 Jul 27.
43 Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693.
44 Sensitization by 5-azacytidine toward death receptor-induced hepatic apoptosis. J Pharmacol Exp Ther. 2009 Jan;328(1):107-15. doi: 10.1124/jpet.108.143560. Epub 2008 Sep 30.
45 Arsenic induces functional re-expression of estrogen receptor by demethylation of DNA in estrogen receptor-negative human breast cancer. PLoS One. 2012;7(4):e35957. doi: 10.1371/journal.pone.0035957. Epub 2012 Apr 27.
46 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
47 Hypomethylation of interleukin-4 and -6 promoters in T cells from systemic lupus erythematosus patients. Acta Pharmacol Sin. 2008 Jan;29(1):105-12. doi: 10.1111/j.1745-7254.2008.00739.x.
48 Differential regulation of the p73 cistrome by mammalian target of rapamycin reveals transcriptional programs of mesenchymal differentiation and tumorigenesis. Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2076-81. doi: 10.1073/pnas.1011936108. Epub 2011 Jan 18.
49 Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate. 2008 May 15;68(7):793-801. doi: 10.1002/pros.20748.
50 Lactate dehydrogenase-B is silenced by promoter methylation in a high frequency of human breast cancers. PLoS One. 2013;8(2):e57697. doi: 10.1371/journal.pone.0057697. Epub 2013 Feb 21.
51 The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake. Cancer Biother Radiopharm. 2007 Jun;22(3):443-9. doi: 10.1089/cbr.2006.319.A.
52 Characterisation of human histone H1x. Biol Chem. 2005 Jun;386(6):541-51. doi: 10.1515/BC.2005.064.
53 Azacytidine induces cell cycle arrest and suppression of neuroendocrine markers in carcinoids. Int J Clin Exp Med. 2010 Mar 28;3(2):95-102.
54 Pharmacologic reductions of total tau levels; implications for the role of microtubule dynamics in regulating tau expression. Mol Neurodegener. 2006 Jul 26;1:6. doi: 10.1186/1750-1326-1-6.
55 Promoter methylation as a common mechanism for inactivating E-cadherin in human salivary gland adenoid cystic carcinoma. Cancer. 2007 Jul 1;110(1):87-95. doi: 10.1002/cncr.22758.
56 15-hydroxyprostaglandin dehydrogenase is down-regulated in gastric cancer. Clin Cancer Res. 2009 Jul 15;15(14):4572-80. doi: 10.1158/1078-0432.CCR-08-2518. Epub 2009 Jul 7.
57 DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol Cell Biol. 2008 Jan;28(2):752-71. doi: 10.1128/MCB.01799-07. Epub 2007 Nov 8.
58 CpG methylation-dependent repression of the human O6-methylguanine-DNA methyltransferase gene linked to chromatin structure alteration. Carcinogenesis. 2003 Aug;24(8):1337-45. doi: 10.1093/carcin/bgg086. Epub 2003 May 22.
59 Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target. Cancer Res. 2009 Feb 15;69(4):1527-35. doi: 10.1158/0008-5472.CAN-08-3609. Epub 2009 Feb 3.
60 The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/?catenin pathway and DNA methyltransferase-1. Oncol Rep. 2017 Nov;38(5):3114-3120. doi: 10.3892/or.2017.5945. Epub 2017 Sep 7.
61 Hypermethylation of Cyclin D2 is associated with loss of mRNA expression and tumor development in prostate cancer. J Mol Med (Berl). 2006 Nov;84(11):911-8. doi: 10.1007/s00109-006-0099-4. Epub 2006 Sep 22.
62 Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol. 2007 Sep;138(5):616-23. doi: 10.1111/j.1365-2141.2007.06707.x.
63 Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103. Cytotherapy. 2011 May;13(5):618-28. doi: 10.3109/14653249.2010.529893. Epub 2010 Dec 20.
64 DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors. Clin Immunol. 2009 Feb;130(2):213-24. doi: 10.1016/j.clim.2008.08.009. Epub 2008 Oct 22.
65 Tamoxifen epigenetically modulates CXCL12 expression in MCF-7 breast cancer cells. Biomed Pharmacother. 2010 Jan;64(1):54-7. doi: 10.1016/j.biopha.2009.04.041. Epub 2009 Sep 2.
66 Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. Leuk Res. 2009 Jul;33(7):891-7. doi: 10.1016/j.leukres.2009.01.041. Epub 2009 Feb 27.
67 5-Azacytidine-treated human mesenchymal stem/progenitor cells derived from umbilical cord, cord blood and bone marrow do not generate cardiomyocytes in vitro at high frequencies. Vox Sang. 2008 Aug;95(2):137-48. doi: 10.1111/j.1423-0410.2008.01076.x. Epub 2008 Jun 28.
68 Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol. 2007 Jun;60(6):664-9. doi: 10.1136/jcp.2006.038331.
69 Methylation status of CpG islands flanking a cAMP response element motif on the protein phosphatase 2Ac alpha promoter determines CREB binding and activity. J Immunol. 2009 Feb 1;182(3):1500-8. doi: 10.4049/jimmunol.182.3.1500.
70 Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood. 2007 Nov 15;110(10):3648-55. doi: 10.1182/blood-2007-06-096701. Epub 2007 Aug 13.
71 A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
72 Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res. 2004 Oct 15;10(20):7100-7. doi: 10.1158/1078-0432.CCR-04-0337.
73 Synergism of arsenic trioxide and MG132 in Raji cells attained by targeting BNIP3, autophagy, and mitochondria with low doses of valproic acid and vincristine. Eur J Cancer. 2014 Dec;50(18):3243-61. doi: 10.1016/j.ejca.2014.09.012. Epub 2014 Oct 13.
74 Promoter hypermethylation of the RUNX3 gene in esophageal squamous cell carcinoma. Cancer Invest. 2007 Dec;25(8):685-90. doi: 10.1080/07357900701561131.
75 [5-azacytidine enhances anti-tumor efficacy of doxorubicin to neuroblastoma cell lines]. Zhongguo Dang Dai Er Ke Za Zhi. 2007 Dec;9(6):577-9.
76 Pyruvate Dehydrogenase Kinase 4 Deficiency Results in Expedited Cellular Proliferation through E2F1-Mediated Increase of Cyclins. Mol Pharmacol. 2017 Mar;91(3):189-196. doi: 10.1124/mol.116.106757. Epub 2016 Dec 21.
77 p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res. 2008 Nov 15;68(22):9358-66. doi: 10.1158/0008-5472.CAN-08-1860.
78 Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer. 2006 Sep;13(3):797-826. doi: 10.1677/erc.1.01143.
79 Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16811-6. doi: 10.1073/pnas.0907109106. Epub 2009 Sep 10.
80 Human concentrative nucleoside transporter 1-mediated uptake of 5-azacytidine enhances DNA demethylation. Mol Cancer Ther. 2009 Jan;8(1):225-31. doi: 10.1158/1535-7163.MCT-08-0743.
81 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.